Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cytek Biosciences, Inc. Market Cap
The Cytek Biosciences, Inc. (CTKB) share price is expected to increase by 28.64% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered CTKB. Price targets range from $7 at the low end to $9 at the high end. The current analyst consensus for CTKB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CTKB is a stock in Healthcare which has been forecasted to be worth $8.4 as an average. On the higher end, the forecast price is $9 USD by Mason Carrico from Stephens & Co. and on the lower end CTKB is forecasted to be $7 by Tejas Savant from Morgan Stanley.
These are the latest 20 analyst ratings of CTKB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Westenberg Piper Sandler | Overweight | $8.5 | Maintains | Nov 11, 2024 |
| David Westenberg Piper Sandler | Overweight | $8 | Maintains | Aug 13, 2024 |
| David Westenberg Piper Sandler | Overweight | $8.5 | Maintains | May 13, 2024 |
| David Westenberg Piper Sandler | Overweight | $10 | Maintains | Mar 6, 2024 |
| Matthew Sykes Goldman Sachs | Buy | $10 | Maintains | Feb 29, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $9 | Initiates | Dec 14, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $7 | Maintains | Nov 9, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $8 | Maintains | Oct 24, 2023 |
| David Westenberg Piper Sandler | Overweight | $10 | Maintains | Oct 16, 2023 |
| Andrew Cooper Raymond James | Market Perform | Initiates | Jul 19, 2023 | |
| Tejas Savant Morgan Stanley | Equal-Weight | $13 | Maintains | May 11, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $12 | Maintains | May 10, 2023 |
| David Westenberg Piper Sandler | Overweight | $15 | Maintains | Mar 7, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $14 | Maintains | Mar 2, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $14 | Maintains | Mar 2, 2023 |
| David Westenberg Piper Sandler | Overweight | $16 | Maintains | Aug 18, 2022 |
| Tejas Savant Morgan Stanley | Equal-Weight | $15 | Maintains | Aug 12, 2022 |
| Matthew Sykes Goldman Sachs | Buy | $17 | Maintains | Aug 11, 2022 |
| Matthew Sykes Goldman Sachs | Buy | $15 | Maintains | Jul 14, 2022 |
| David Westenberg Piper Sandler | Overweight | $12 | Maintains | May 16, 2022 |
When did it IPO
2021
Staff Count
645
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Wenbin Jiang Ph.D.
Market Cap
$841.1M
In 2023, CTKB generated $193.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CTKB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytek Biosciences, Inc. (Nasdaq: CTKB) was awarded "Overall BioTech Company of the Year" in the 2024 BioTech Breakthrough Awards program.
Why It Matters - Cytek Biosciences' recognition as "Overall BioTech Company of the Year" may enhance its market reputation, potentially leading to increased investor interest and stock performance.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytek Biosciences, Inc. (Nasdaq: CTKB) will participate in the Piper Sandler 36th Annual Healthcare Conference in New York, scheduled for November 2024.
Why It Matters - Cytek Biosciences' participation in a major healthcare conference may enhance visibility, attract investors, and signal potential growth opportunities in the cell analysis market.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytek Biosciences, Inc. has launched an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system, enhancing its product offerings.
Why It Matters - The introduction of the ESP™ Detection Option enhances Cytek's product capabilities, potentially increasing demand, revenue, and market position, which can positively impact stock performance.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cytek Biosciences, Inc. (NASDAQ:CTKB) will hold its Q3 2024 Earnings Conference Call on November 5, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters - Cytek Biosciences' earnings call may reveal financial performance, strategic updates, and future outlook, influencing stock valuation and investor sentiment.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cytek Biosciences (CTKB) reported Q3 earnings of $0.01 per share, surpassing the Zacks estimate of a $0.02 loss, and matching the earnings from the same quarter last year.
Why It Matters - Cytek Biosciences' earnings beat expectations, indicating stronger financial performance and potential growth, which may boost investor confidence and stock value.
Wed, 18 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytek Biosciences, Inc. (Nasdaq: CTKB) will enhance its visibility at major clinical industry events worldwide in 2024.
Why It Matters - Cytek Biosciences’ increased presence at major clinical events signals growth potential and enhanced visibility, likely attracting investor interest and possibly affecting stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
